GIST Support International - logo

GIST Support International - GIST In the News
GIST Imagery

Study finds new designer drug is potent treatment for chronic myelogenous leukemia

Posted by Administrator (admin) on Mar 17 2006
GIST In the News >>

Hybrid targeted therapy effective in treating Gleevec-resistant disease

BOSTON--Using rational drug design strategies, investigators at Dana-Farber Cancer Institute and Novartis Pharmaceuticals in Basel, Switzerland have created a targeted therapy for chronic myelogenous leukemia (CML) that may ultimately be more effective than Gleevec®, the current frontline treatment. The researchers report in the February issue of Cancer Cell that the new compound, AMN107, is about 20 times more potent than Gleevec and is effective in treating Gleevec-resistant disease in model systems.

"While Gleevec represents a major treatment advance for CML – approximately 95 percent of patients treated with Gleevec achieve remission – there clearly is a need for therapies that produce longer remissions, are active against advanced disease, and can be used when Gleevec loses effectiveness," says Dana-Farber's James Griffin, MD, senior author of the study. "The goal of this study was to develop a drug that hits the same target on CML cells as Gleevec does, and to hit more of the target."

Full Text at: http://www.eurekalert.org/pub_releases/2005-02/dci-sfn021105.php

Last changed: Mar 17 2006 at 2:06 PM

Back

back to top